Skip to main content

Lupus clinical trials at UCSD
8 in progress, 3 open to new patients

  • A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE

    open to eligible people ages 18-99

    To compare the effect of RAYOS® versus immediate-release (IR) prednisone on fatigue as measured by Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F).

    San Diego, California and other locations

  • A Phase 2a of RSLV-132 in Subjects With Systemic Lupus Erythematosus (SLE)

    open to eligible people ages 18-70

    This study evaluates the impact of 13 bi-weekly intravenous infusions of RSLV-132 on the cutaneous manifestations in subjects with systemic lupus erythematosus.

    La Jolla, California and other locations

  • Safety and Efficacy of Filgotinib and GS-9876 in Adults With Lupus Membranous Nephropathy (LMN)

    open to eligible people ages 18-75

    The primary objective of this study is to evaluate the efficacy of filgotinib and GS-9876 in adults with Lupus Membranous Nephropathy (LMN).

    La Jolla, California and other locations

  • A Study of Baricitinib in Participants With Systemic Lupus Erythematosus

    Sorry, not currently recruiting here

    The reason for this study is to see how effective and safe the study drug known as baricitinib is in participants with systemic lupus erythematosus (SLE).

    La Jolla, California and other locations

  • A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN)

    Sorry, in progress, not accepting new patients

    This Phase II study will compare the efficacy and safety of obinutuzumab plus mycophenolate mofetil (MMF)/mycophenolic acid (MPA) with placebo plus MMF/MPA in participants with proliferative LN.

    La Jolla, California and other locations

  • JBT-101 in Systemic Lupus Erythematosus (SLE)

    Sorry, not currently recruiting here

    The objective of this study is to evaluate the efficacy, safety, and tolerability of JBT-101 (also known as lenabasum) in systemic lupus erythematosus (SLE). - One hundred adults with active joint disease and at least moderate pain will be enrolled in this study to evaluate treatment of their systemic lupus erythematosus (SLE) with JBT-101. JBT-101 is a synthetic endocannabinoid receptor type 2 (CB2) agonist and an activator of the body's normal processes, to resolve innate immune responses without immunosuppression. - Participants will receive 2 doses of JBT-101 by mouth (three groups of varying doses) or, placebo, for 84 days and will continue to be followed for an additional 28 days. Participant visits to assess endpoints occur on Day 1, then every 2 weeks twice, then every 4 weeks three times, for a total of six visits. - The change in maximum daily pain Numerical Rating Scale (NRS) score from Baseline (Visit 1) will be assessed at every visit.

    La Jolla, California and other locations

  • Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE)

    Sorry, not yet accepting patients

    The purpose of this study is to evaluate the efficacy and safety of mesenchymal stem cells (MSCs) obtained from umbilical cords for the treatment of adults with systemic lupus erythematosus (SLE). The goal of this study is to determine if patients receiving an MSC infusion plus standard of care respond better than patients receiving placebo infusion plus standard of care.

    San Diego, California and other locations

  • Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE)

    Sorry, in progress, not accepting new patients

    This trial seeks to describe the effect of withdrawal from mycophenolate mofetil (MMF) on risk of clinically significant disease reactivation in quiescent SLE patients who have been on long-term MMF therapy.

    San Diego, California and other locations

Last updated: